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Executive Summary 
Heart failure (HF) exacerbation is a major source of hospitalization, mortality, and 
healthcare cost to home health agencies.  Unmonitored accumulative fluid retention between 
skilled nurse visits, base knowledge deficits in HF pathophysiology and dietary restrictions, and 
lack of basic monitoring equipment such weighing scales are primary contributors to HF related 
hospitalizations in the home health setting.  It has been discovered that early recognition of 
decompensating HF can reduce or eliminate HF related hospitalization, mortality, and healthcare 
costs associated with the management of exacerbation.  When a patient is sent to the emergency 
room (ER) for fluid overload secondary to HF, massive costs are generated including ER 
transportation, ER consultation fees, hospital stay fee if admitted, and increased home health 
visit fees for adding additional skilled nurse visits for follow up assessments.  Having a method 
of filling in the monitoring gaps of this patient population can reduce negative outcomes 
associated with managing HF in home health.  
The current method of monitoring weekly or bi-weekly by a skilled nurse in these 
complex HF patients is not best practice.  For patients to receive improved and effective HF 
monitoring on non-skilled nurse days, additional monitoring options should be implemented.  
Technological advancement in modern healthcare allows the integration of technology to aide in 
reducing the negative impact HF exacerbation has on home health agencies.  Telemonitoring 
(TM) heart failure in the home health setting is an evidence-based implementation option to 
reduce patient mortality, decrease healthcare costs, and assist healthcare providers in accessing 
current and relevant data for point-of-care decision making.  TM devices should be installed in 
the homes of patients who meet the HF exacerbation risk criteria to reduce hospitalization, 
mortality, and healthcare costs. 
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Rationale 
Patients in home health often receive inadequate HF monitoring with severe negative 
consequences.  The primary internal reasons for lack of adequate HF monitoring include staffing 
inadequacies, insurance providers refusing to pay for additional skilled nurse visits, patients 
having moderate to severe knowledge deficits in HF disease process management, and lack of 
hemodynamic monitoring equipment.  Unfortunately, HF related hospitalizations continue to 
occur frequently incurring severe negative consequences affecting all health care disciplines 
involved.   
The exponential financial burden of multiple heart failure related hospitalizations has 
warranted investigation in alternative evidence-based methods of HF monitoring as it is the role 
of the clinician to identify organizational change needed and to find the best available evidence 
to support this change (Melnyk & Fineout-Overholt, 2015).  Creating an avenue for daily home 
monitoring of HF by skilled clinicians allows for rapid assessment and intervention that may 
otherwise not have taken place.  This provides the opportunity to contact primary care providers 
for pharmacological intervention to reduce HF related hospitalization and mortality.   
The goal of this benchmark project is to bring light to the fact that the current system of 
monitoring HF in this patient demographic is not effective and should be changed.  The primary 
rationale of searching for HF monitoring solutions arose from multiple internal documented 
cases of HF exacerbation in patients who met the criteria for TM devices but did not have them 
available.  As more insurance companies switch to pay for performance reimbursement 
strategies, reimbursement rates for HF patients with preventable hospitalization will likely 
decline, further inflating the cost of caring for these patients.  The goal of this project is using the 
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implementation of TM devices in qualifying patient homes to reduce HF related hospitalization, 
mortality, healthcare costs, and reduce negative outcomes. 
Literature Synthesis 
The literature search was conducted using the Cumulative Index to Nursing and Allied 
Health Literature Database, Cochrane Library, and PubMed.  The criteria included the keywords 
“telemonitoring” and “heart failure”.  Only articles including patients over the age of 60 with a 
diagnosis of heart failure and active cardiac telemonitoring with the highest available levels of 
evidence were utilized.  Gensini, Alderighi, Rasoini, Mazzanti, and Casolo (2017) stated, “It is 
crucial to identify the most relevant biological parameters to monitor, which heart failure sub-
populations may gain real benefits from telehealth interventions and in which specific healthcare 
subsets these interventions should be implemented in order to maximize value” (p. 116).  To 
support the feasibility and applicability of the implementation of TM into home health practice, 
multiple randomized control trials (RCT), meta-analyses (MA) were thoroughly reviewed.   
The primary beneficial factors sought for the benchmark project were decreased HF 
hospitalization and mortality rates.  Several studies clearly showed the benefit of TM 
implementation.  An overview of 19 systematic reviews found that TM was effective in reducing 
mortality and heart failure rehospitalization (Bashi et al., 2017).  This study specifically included 
rehospitalization as part of the review process.  Boyne et al. (2017) found that tailored TM 
improved patient education and self-efficacy.  These are factors that are crucial for long-term 
management of HF.  A RCT by Delaney et al. (2013) found that TM significantly reduced 
hospitalization and increased HF related knowledge compared to the group with no TM.  An 
additional RCT found that using TM to track and improve adherence to HF medications 
including diuretics showed to be beneficial to most HF patients (Gallagher et al., 2017).  A 
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unique RCT that studied implant-based TM directly showed a significant improvement in 
clinical outcomes and a strong recommendation for TM practice implementation (Hindricks et 
al., 2014).  A MA by Kitsiou et al. (2015) found home TM reduced the relative risk of all-cause 
mortality and HF related hospitalization.  This finding was significant in the fact that it related 
specifically to the benchmark project goals.   
A review of over 30 RCT with more than 10,000 patients found that TM reduced the 
odds of mortality and hospitalization in HF patients compared to not using TM (Kotb et al., 
2015).  A study design that used TM tablet computers in the home found that HF knowledge and 
health related quality of life increased significantly while decreasing hospitalization (Melin et al., 
2018).  It was important during the article search that evidence was obtained that supports long 
term application of TM.  A MA by Tse et al. (2018) found that TM reduced HF related 
hospitalization in both the short and long-term.  A MA of 37 RCT with 9582 patients concluded 
that TM intervention reduced mortality risk associated with HF and found that increasing the 
frequency of TM data transmission was associated with increased effectiveness (Yun et al., 
2018).  An additional supporting MA with 29 RCT and 10,981 patients concluded that TM 
reduced HF mortality, hospitalizations, and additionally reduced the length of hospital stay (Zhu 
et al., 2019).  The supporting evidence that provided the benefit of TM implementation was 
substantial. 
Stakeholders 
 The internal stakeholders of the project who are directly affected include the executive 
director (ED), director of patient care services (DPCS), and senior vice president (SVP) of the 
region.  The DPCS is the first to know about the implementation of any new projects.  Once 
cleared and approved by the DPCS, the ED is notified for a review of the project goals.  The 
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ultimate authority for implementation in turn is greenlighted by the regional SVP.  If the 
benchmark project is implemented nationally, additional corporate stakeholders may be indicated 
for consultation and approval.   
External stakeholders and those indirectly affected include the Cardio-com TM team as 
suppliers and the patients as customers.  Additional stakeholders include the providers 
responsible for ordering home health and the payors responsible for paying for covered services.  
The stakeholder’s primary desires include reliable and functional telemonitoring devices to 
provide quality data that is easily interpretable.  The rationale for this stakeholder preference is 
decreased failure rate from the telemonitoring device to provide the most accurate data to prevent 
heart failure hospitalization, decreasing healthcare costs. 
Implementation 
 The benchmark project implementation plan is straightforward.  An overview of the 
implementation plan includes obtaining the TM devices, setting up the software, selecting the 
patient population and staff, setting up the TM devices in the patient homes, and monitoring and 
acting on the provided data to identify and intervene when heart failure exacerbation is 
suspected.  The first step in implementing this project includes contacting the Cardio-com TM 
device distributor and renting the number of TM devices that fits the specified patient population 
and specific agency needs.  Once the TM devices are rented, the manufacturer will ship and 
deliver the TM devices to the agency of choice so they will be available for distribution to the 
qualifying homes.  The second step of implementation includes registering the devices after they 
are delivered and downloading the monitoring software to existing company laptops.  The third 
step of implementation includes determining the patient population that will receive the TM 
devices.  Ideally this will include patients 60 years and older with heart failure.  The fourth step 
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of implementation includes selecting staff members who are responsible for daily monitoring of 
the data and notifying the ordering provider for notification parameter orders and any standing 
diuretic or other intervention orders.  The fifth step of implementation includes installing the TM 
devices in the patient homes and instructing the patients on how to transmit data and to perform 
data transmission once daily for review.  The sixth and final step of the implementation project 
includes monitoring the transmitted data for timely intervention.  The staff will be alerted to 
patients reporting signs or symptoms of heart failure including increased shortness of breath, 
decreased urination, orthopnea, activity intolerance, edema, and weight increase as well as 
medication compliance.  
Timetable 
 The timeline for the benchmark project implementation is designed so the 
implementation phase can be completed in ten days or less for maximal benefit to the patient 
through early intervention.  The first step of contacting the Cardio-com TM device distributor, 
renting the number of TM devices that fits the specified patient population and specific agency 
needs, and the delivery of the devices from the manufacturer should be completed on days one 
through three.  The second step of registering the devices after they are delivered and 
downloading the monitoring software to existing company laptops should be completed by days 
four through five.  The third step of determining the patient population that will receive the TM 
devices should occur between days six through seven.  The fourth step of selecting staff 
members who are responsible for daily monitoring of the data and notifying the ordering 
provider for notification parameter orders and any standing diuretic or other intervention orders 
should occur between days six through seven.  The fifth step of installing the TM devices in the 
patient homes and instructing the patients on how to transmit data and to perform data 
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transmission once daily for review should occur between days eight through nine.  The sixth and 
final step of monitoring the transmitted data for timely intervention should occur no later than 
ten days following the initiation of the implementation to allow maximum benefit to the agency 
and the patient. 
Flowchart  
Day 1-3 Day 4-5 Day 6-7 Day 8-9 Day 10+ 
Rent Cardio-
com devices 
 
Register and set 
up software 
 
Select staff and 
patients  
 
Install devices in 
patient homes 
and educate 
patients on use 
 
Monitor data and 
intervene 
appropriately 
with patients, 
providers, and 
staff  
 
Data Collection Methods 
 The data collection methods used for the implementation and evaluation in this 
benchmark project are straightforward.  It includes measuring pre-project implementation 
hospitalization and mortality rates in the target patient population and comparing the data to 
post-project implementation hospitalization and mortality rates in the target patient population 
after 3 months.  All patients participating in telemonitoring are flagged in the electronic health 
record as a participant and care and hospital tracking is delivered as usual.  At the end of the 
project period, a comparison will be made to determine the efficacy of the implementation.  
Evaluating outcomes is a critical component to deliver high quality and cost-effective healthcare 
(Melnyk & Fineout-Overholt, 2015).   
Cost and Benefit Discussion 
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Several studies exist showing the benefit of initiating TM in the home care setting to 
reduce heart failure related hospitalization.  O’Connor et al. (2016) reported, “Telehealth was 
associated with a reduction in all-cause 30-day readmission for one mid-sized Medicare-certified 
home health agency” (p. 238).  For TM to be cost effective when initiated in a facility, guidelines 
and a clear protocol must be in place for the proper collections and translation of data.  Evidence 
based practice guidelines can potentially improve health outcomes and organizational 
performance (Melnyk & Fineout-Overholt, 2015).  The cost of a renting a single Cardio-com TM 
device is $100.00 per month per patient.  This includes all software and software updates and 
maintenance.  The cost of a single extra skilled nursed visit is billed around $150.00 per oasis 
visit.  The cost of additional routine visits are billed at around $90.00 per visit.  The cost of 
losing Medicare payment for a home health episode, based on the target population, is 
approximately $1780.00.  If one patient were to be admitted to the hospital via ambulance 
transport and ER for HF exacerbation, the cost would be approximately $30,000.00.  This is 
enough for one patient to have access to a Cardio-com TM device for 25 years.  The other 
obvious benefits of this project include decreased healthcare costs outside of the agency as well 
as decreased burden on the healthcare system.  The benefit is very clear, if one episode of 
payment is retracted due to HF hospitalization and negative outcomes, the agency loses enough 
money to fund almost six more patients to have TM devices.  In the case of TM versus no TM, 
the benefit outweighs the cost burden. 
Overall Discussion and Results 
The projected results of this benchmark project are based on reviewing evidence-based 
literature and developing a plan to implement and utilize this benefit in professional practice.  It 
was discovered that decreased hospitalization and mortality rates for HF patients in the home 
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care setting is obtainable through the implementation of TM.  Multiple RCT and MA across 
thousands of patients provide profound evidence of the projected benefit of the implementation 
of this benchmark project.  The patient must be treated as an equal partner for success of the 
project implementation (Melnyk & Fineout-Overholt, 2015).  When a change project is 
completed and guidelines are in place, it is important to develop methods for long term 
sustainment of the project.  Even with the best plans and guidelines, the dissemination of your 
findings is not enough for healthcare workers to change their daily practice (Gameiro et al., 
2019).  It is also important that clear and concise communication be made with staff members to 
assist in decreasing confusion during the project.  The review and consideration of this 
benchmark project allows professionals to be informed on the use of technology to provide 
evidence-based application to reduce HF related hospitalization in patients 60 years and older. 
Recommendations 
Based on the evidence presented in this benchmark project, TM in the home care setting 
to reduce HF related hospitalization and mortality should be recommended for all home health 
agencies treating HF patients 60 and over.  The next steps include informing others of the real-
world effectiveness of utilization technology to monitor chronic disease and reduce preventable 
hospitalizations.  It is recommended that during the implementation of a project, the nurse should 
create an environment that is favorable for trust and respect that maximally benefits the patient 
and healthcare worker.  In order to successfully integrate evidence-based practice into an 
organization, you must have the willingness to change and the tools necessary to implement the 
project.  Organization change is a highly emotional process requiring the tools of strong 
leadership willingness to change (Melnyk & Fineout-Overholt, 2015).  Change management 
requires determination and excellent communication.  It is recommended that this project be 
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implemented into organizational practice for maximal benefit to the organization and patients.  
Finally, it is recommended that colleagues, patients, and leadership staff adopt similar strategies 
to incorporate and translate evidence-based results into practice. 
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Appendix 
Evaluation Table 
 
PICOT Question: For patients 60 years and older with heart failure (P), how does the use of cardiac 
telemonitoring (I) compared to no cardiac telemonitoring (C) affect the risk of hospitalization (O) over a three-
month period (T)? 
 
PICOT Question Type (Circle): Intervention   Etiology    Diagnosis or Diagnostic Test    Prognosis/Prediction   
Meaning 
 
Caveats  
1) The only studies you should put in these tables are the ones that you know answer your 
question after you have done rapid critical appraisal (i.e., the keeper studies) 
2) Include APA reference 
3) Use abbreviations & create a legend for readers & yourself 
4) Keep your descriptions brief – there should be NO complete sentences 
5) This evaluation is for the purpose of knowing your studies to synthesize. 
 
Place your APA Reference here (Use correct APA reference format including the hanging 
indentation):  
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AR 21  
No FU 
 
3 hospitals 
South of 
Netherlands  
 
October 
2007 
December 
2008 
IV 1 
TM 
 IV 2 
UC 
 DV 
Improve 
self-care 
abilities 
and sense 
of self-
efficacy 
 
BEES 
Barnason 
et al. 
CA 0.837 
 
DHFKS 
Van der 
Wal et al. 
CA 0.62 
 
EHFSCB 
Jaarsma et 
al. 
CA 0.80 
 
 
STT 
 
MWU 
 
Disease-
specific 
knowledge  
TM 12.6 
C 12.3 
p = 0.09 
 
Self-care 
TM 18.9 
C 20.9 
p = 0.001 
 
Self-
efficacy  
TM 53.2 
C 51.1 
p = 0.024 
 
Mean 
knowledge 
score 
TM 12.6  
C 12.3  
p = 0.09 
 
Overall 
complianc
e 
TM 92.3% 
IQR 84.7–
94.9 
 
Strengths 
RCT 
n calculation based on HF admissions  
DC of TM and UC 
 
Limitations 
QQD 
 
NSR 
 
TM technique feasible for practice 
use 
 
Intervention PICOT/RCT level II 
evidence 
Quality of evidence strong 
USPSTF Grade C 
Moderate level of certainty 
 
Delaney et 
al. 
 
2013 
 
A 
randomize
d trial of 
telemonito
ring and 
self-care 
Self-care 
manage
ment 
RCT 100 P 
50 TM 
50 UC 
 
Age >21 
MA 80 
 
Discharged 
to home 
health  
 
IV 1 
TM 
 
IV 2 
UC 
 
DV 
Decreased 
hospitaliza
tion, 
improved 
DHFKS 
Van der 
Wal et al. 
CA 0.62 
 
ANO
VA 
 
PCS 
 
LR 
MLHF 
scores 
TM (mean 
= 32.1; SD 
= 15.3, p = 
.004) 
C (mean = 
42.4; SD 
16.7) 
 
Strengths  
RCT 
DC of TM and UC 
Racial/ethnic diversity  
 
Limitations 
Short FU time  
 
NSR 
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education 
in heart 
failure 
patients 
following 
home care 
discharge 
NYHA III, 
IV 
 
AR 7  
Died 
Refused 
installation  
Dropped 
out 
 
Home care 
agency in 
Connecticut 
 
90 days 
QOL, 
increased 
HF 
knowledge 
at 90 days 
following 
home care 
discharge 
 
 
HF 
knowledge  
TM 11.78 
(1.8) 13.10 
(2.2) F = 
6.40 β = 
.225 
C 11.03 
(2.4) 11.37 
(1.9) p = 
.013 p = 
.039 
 
QOL 
C 42.94 
(16.2) 
42.42 
(16.7) p = 
.004 p = 
.011 
TM 41.57 
(18.3) 
32.10 
(15.3) F = 
8.66 β = –
.278 
 
 
TM technique feasible for practice 
use 
 
Intervention PICOT/RCT level II 
evidence 
Quality of evidence strong 
USPSTF Grade C 
Moderate level of certainty 
Feltner et 
al. 
 
 
NR SR 15,999 P 
 
47 RCT 
 
MA 70 
 
NYHA I-
IV 
EF <45% 
 
>6 month 
intervention 
IV 1 
TM 
 
IV2 
UC 
 DV 
Reduced 
HF 
mortality 
and 
hospitaliza
tion risk 
NR RR Home 
visits vs. 
UC 
RR, 0.34  
95% CI 
0.19 to 
0.62 
Strengths 
SR of RCT 
DC of TM and UC 
Diverse interventions 
 
Limitations 
Usual care not adequately described 
 
NSR 
 
TM technique feasible for practice 
use 
 
Intervention PICOT/SR level I 
evidence 
Quality of evidence strong 
USPSTF Grade B 
High level of certainty 
Gallagher 
et al.  
 
2017 
 
Telemonit
oring 
adherence 
to 
medication
s in heart 
failure 
patients 
(TEAM-
HF): A 
pilot 
randomize
d clinical 
trial 
NR RCT 40 P 
20 TM 
20 UC 
 
Age >21 
MA 64 
 
Discharged 
on loop 
diuretic  
 
NYHA I, 
II, or III 
 
MEF 25 % 
 
AR 4 
No device 
use 
 
New York–
Presbyteria
n Hospital  
 
IV 1 
TM  
 
IV 2 
UC 
 
DV 
Loop 
diuretic 
adherence 
after 
discharge  
 
NR MWU 
 
PCS 
 
FET 
 
IQR 
10 P 
readmitted 
< 30 days 
 
Adherent 
to diuretics 
TM 10 
C 9 
p = 0.49 
 
Correct 
dosing 
TM 81.8 
C 73.3 
p = 0.41 
IQR 47–
94% 
 
Attended 
30 day FU 
TM 19 
C 16 
p = 0.34 
 
Strengths  
RCT 
DC of TM and UC 
New study type 
Racial/ethnic diversity  
 
Limitations 
Short FU time  
No confirmation of ingestion  
Nonadherent patients not targeted 
Privacy concerns  
 
NSR 
 
TM technique feasible for practice 
use 
 
Intervention PICOT/RCT level II 
evidence 
Quality of evidence strong 
USPSTF Grade C 
Moderate level of certainty 
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December 
2014 to 
August 
2015 
 
Hindricks 
et al. 
 
2014 
 
Implant-
based 
multipara
meter 
telemonito
ring of 
patients 
with heart 
failure 
(IN-
TIME): A 
randomise
d 
controlled 
trial 
NR RCT 664 P 
333 TM  
331 UC  
 
Age >18 
MA 65.5 
 
Chronic HF 
>3 months 
 
NYHA  II, 
or III 
 
MEF 26 % 
 
AR 30 
TP          
Died    
Lost to 
follow-up  
WC 
 
36 tertiary 
clinical 
centres, in 
Australia, 
Europe, and 
Israel 
IV 1 
TM 
 
IV 2 
UC 
 
DV 
Improved 
clinical 
outcomes 
Decreased 
all cause 
mortality 
 
NR MWU 
 
PCS 
 
CR 
 
KMM 
 
OR 
Hospital 
admissions 
TM 44 
C 47  
 
1-year 
cardiovasc
ular 
mortality 
TM 2.7%  
C 6.8% 
 
Worsening  
NYHA 
functional 
class 
TM 29 
C 35 
 
Worsening  
composite 
clinical 
score 
TM 63 
C 90 
 
95% CI 
 
 
Strengths 
RCT 
DC of TM and UC 
Moderate sample size 
 
Limitations 
Inability to mask 
patients/investigators to treatment 
allocation 
Medium-term length of follow-up 
Did not enforce standardized 
treatment after TM observations 
 
NSR 
 
TM technique feasible for practice 
use 
 
Intervention PICOT/RCT level II 
evidence 
Quality of evidence strong 
USPSTF Grade C 
Moderate level of certainty 
 
Kitsiou et 
al. 
 
2014 
 
Effects of 
home 
telemonito
ring 
interventio
ns on 
patients 
with 
chronic 
heart 
failure: An 
overview 
of 
systematic 
reviews. 
 
NR SR 15 SR 
 
MA 48-83 
 
NYHA I-
IV 
EF <45% 
 
>6 month 
intervention 
IV 1 
TM 
 
IV2 
UC 
 DV 
Reduced 
HF 
mortality 
and 
hospitaliza
tion risk 
NR NR OR 0.60 
CI 95% 
 
Improvem
ents in HF 
hospitaliza
tions 
HR 0.70  
95% 
credible 
interval 
Crl 0.34-
1.5 
Strengths 
SR of RCT 
DC of TM and UC 
Diverse interventions 
 
Limitations 
Some evidence not focused on less 
common TM methods 
 
NSR 
 
TM technique feasible for practice 
use 
 
Intervention PICOT/SR level I 
evidence 
Quality of evidence strong 
USPSTF Grade B 
High level of certainty 
Kotb et al. 
 
2015 
 
Comparati
ve 
effectivene
ss of 
different 
forms of 
telemedici
ne for 
individuals 
with heart 
failure 
NR SR 
MET
A 
10,193 P 
 
30 RCT 
 
MA 65 
 
Majority 
male 
 
NYHA I-
IV 
EF <45% 
 
>6 month 
intervention 
IV 1 
TM 
 
IV2 
UC 
 DV 
Reduced 
HF related 
death and 
hospitaliza
tion 
 
 
NR OR Mortality  
TM 0.53 
OR 
 
HF 
Hospitaliz
ation 
TM 0.64 
OR 
 
 
 
Strengths 
SR of RCT 
META 
DC of TM and UC 
>6 month FU 
 
Limitations 
Available evidence not focused on 
less common methods 
 
NSR 
 
TM technique feasible for practice 
use 
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(HF): A 
systematic 
review and 
network 
meta-
analysis 
Intervention PICOT/SR level I 
evidence 
Quality of evidence strong 
USPSTF Grade B 
High level of certainty 
 
Melin et 
al. 
 
2018 
 
Effects of 
a tablet 
computer 
on self-
care, 
quality of 
life, and 
knowledge
: A 
randomize
d clinical 
trial 
NR RCT 72 P 
 
MA 75 
 
NYHA III 
 
Acute HF 
or FU 4 
weeks 
 
AR 14 
Died 
Withdrew 
consent 
 
3 university 
hospitals in 
Stockholm 
Sweden 
IV 1 
TM 
 
IV2 
UC 
 DV 
Improved 
self-care 
behavior, 
QOL, 
increased 
HF 
knowledge
, reduced 
hospital 
days 
DHFKS 
Van der 
Wal et al. 
CA 0.62 
 
EHFSCB 
Jaarsma et 
al. 
CA 0.80 
 
MWU 
 
IQR 
Self Care 
TM 16.5  
IQR 12-22 
C 23.5  
IQR 18.8-
30.0 
P < .05 
 
QOL 
TM 72.7 
IQR 50.8-
87.9 
C 51.8 
IQR 40.9-
62.8 
P < .05 
 
HF 
hospitaliza
tion  
TM 6.9 (6 
months) 
C 9.6 (6 
months) 
Strengths  
RCT 
DC of TM and UC 
Sustained results at 6 months 
 
Limitations 
Increased AFIB in C 
 
NSR 
 
TM technique feasible for practice 
use 
 
Intervention PICOT/RCT level II 
evidence 
Quality of evidence strong 
USPSTF Grade C 
Moderate level of certainty 
Tse et al. 
 
2018 
 
Telemonit
oring and 
hemodyna
mic 
monitoring 
to reduce 
hospitaliza
tion rates 
in heart 
failure: A 
systematic 
review and 
meta-
analysis of 
randomize
d 
controlled 
trials and 
real-world 
studies 
NR SR 
MET
A 
31,501 P 
 
55 RCT 
 
61% male 
 
MA 68 
 
PubMed 
Cochrane 
Library 
 
FU 
duration 11 
months 
IV 1 
TM 
 
IV2 
UC 
 DV 
Reduced 
HF 
hospitaliza
tion short 
and long 
term 
JS 
Jadad et 
al. 
NCAR 
PCS 
 
CQT 
TM 
reduced 
hospitaliza
tion 
HR 0.73 
95% CI 
0.65-0.83 
P < 0.0001 
 
HF 
hospitaliza
tion short 
term 
HR = 0.77 
0.65-0.89 
P < 0.01 
 
HF 
hospitaliza
tion long 
term 
HR = 0.73 
95% CI 
0.62-0.87 
P < 0.0001 
Strengths 
SR of RCT 
META 
DC of TM and UC 
 
Limitations 
Lack of comparison of TM to HDM 
Heterogeneity for HR for effects of 
TM on hospitalization 
 
NSR 
 
TM technique feasible for practice 
use 
 
Intervention PICOT/SR level I 
evidence 
Quality of evidence strong 
USPSTF Grade B 
High level of certainty 
 
Yun et al. 
 
2018 
 
Comparati
ve 
effectivene
ss of 
telemonito
ring versus 
usual care 
for heart 
failure: A 
systematic 
review and 
NR SR 
MET
A 
9582 P 
 
MA 67.7 
 
NYHA III-
IV 
 
Ovid-
Medline 
Ovid-
Embase 
Cochrane 
Library 
 
USA 
IV 1 
TM 
 
IV2 
UC 
 DV 
Reduced 
HF 
mortality 
and 
hospitaliza
tion risk 
NR CQT HR 
mortality 
RR 0.68 
95% CI 
0.50–0.91 
 
QOL 
Depression  
−36% 
P < .0001 
Anxiety 
−38% 
P <.0001 
 
Strengths 
SR of RCT 
META 
DC of TM and UC 
 
Limitations 
C group composition varied 
No total duration of hospitalization 
data 
 
NSR 
 
TM technique feasible for practice 
use 
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meta-
analysis 
Europe Medicatio
n 
adherence 
RR 0.73 
95% CI 
0.61–0.87 
Intervention PICOT/SR level I 
evidence 
Quality of evidence strong 
USPSTF Grade B 
High level of certainty 
 
Zhu et al. 
 
2019 
 
Effectiven
ess of 
telemedici
ne systems 
for adults 
with heart 
failure: A 
meta-
analysis of 
randomize
d 
controlled 
trials 
NR MET
A 
10,981 P 
 
29 RCT 
 
FU 
1-36 
months 
 
NYHA I/IV 
 
EF <45% 
 
 
PubMed 
MEDLINE 
EMBASE 
Cochrane 
Library 
IV 1 
TM 
 
IV2 
UC 
 DV 
Reduced 
HF 
hospital 
admission
s 
Reduced 
HF 
mortality 
NR OR 
 
CQT 
TM 
reduced 
hospitaliza
tion 
OR 0.82 
95% CI  
0.73–0.91 
P=0.0004 
 
TM 
reduced 
HF 
hospitaliza
tion 
OR 0.83 
95% CI  
0.72–0.95 
P=0.007 
 
TM 
reduced 
mortality 
OR 0.75 
95% CI  
0.62–0.90 
P=0.003 
 
Strengths 
META 
DC of TM and UC 
 
Limitations 
Some trials underpowered 
Some endpoint data unavailable 
 
NSR 
 
TM technique feasible for practice 
use 
 
Intervention PICOT/META level I 
evidence 
Quality of evidence strong 
USPSTF Grade B 
High level of certainty 
 
Legend:  
 
(AFIB) atrial fibrillation  
(ANOVA) analysis of variance  
(AR) attrition rate 
(BEES) Barnason Efficacy Expectation Scale  
(C) control  
(CA) Cronbach’s alpha  
(CI) confidence interval 
(CQT) Cochran's Q test 
(CR) Cox regression 
(DC) direct comparison 
(DHFKS) Dutch HF Knowledge Scale 
(EF) ejection fraction 
(EHFSCB) European Heart Failure Self-care Behaviour scale  
(FET) Fisher's exact test 
(FU) follow up 
(HDM) hemodynamic monitoring  
(HF) heart failure 
(HR) hazard ratio 
(IQR) interquartile population range 
(JD) Jadad scale 
(KMM) Kaplan–Meier method 
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(LR) linear regression 
(MA) median age 
(MEF) median ejection fraction 
(META) meta-analysis 
(MLHF) Minnesota living with heart failure questionnaire  
(MR) meta-regression 
(MWU) Mann–Whitney U test 
(n) sample size 
(NCAR) no Cronbach’s alpha reported 
(NR) none reported 
(NSR) no significant risks 
(NYHA) New York Heart Association 
(OR) odds ratio 
(p) p-value 
(P) participants 
(PCS) Pearson's chi-squared 
(PR) peer reviewed  
(PRISMA) preferred reporting items for systematic reviews and meta-analyses 
(QQD) quantitative questionnaire design 
(QOL) quality of life  
(RCT) randomized control/clincal trial 
(RR) risk ratio 
(SD) standard deviation 
(SR) systematic review 
(STT) student t-test 
(TM) telemonitoring  
(TP) terminated prematurely  
(UC) usual care 
(USA) United States of America 
(WC) withdrew consent 
 
***Prompts for each column – please do not repeat the headings, just provide the data                                                                                   
Used with permission, © 2007 Fineout-Overholt 
 
